MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
Portfolio Pulse from Benzinga Newsdesk
Mind Medicine (MindMed) Inc (NASDAQ:MNMD) announced the upcoming presentation of preclinical data of MM-402, its proprietary form of the R-enantiomer of 3,4-Methylenedioxymethamphetamine (MDMA), in a model for autism spectrum disorder (ASD) at the 36th Annual ECNP Congress. The company plans to initiate its first clinical trial of MM-402 in Q4 2023.
October 03, 2023 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MindMed's announcement of the upcoming presentation of preclinical data of MM-402 and the initiation of its first clinical trial in Q4 2023 could potentially boost investor confidence.
The announcement of the upcoming presentation of preclinical data and the initiation of the first clinical trial of MM-402 indicates progress in MindMed's product pipeline. This could potentially boost investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100